Objective: Current guidelines recommend enteral nutrition in critically ill adults; however, poor gastric motility often prevents nutritional targets being met. We hypothesized that early nasojejunal nutrition would improve the delivery of enteral nutrition.
N utritional therapy in the critically ill improves wound healing (1) , reduces complication rates (2) , and may even improve mortality (3) . Current evidencebased clinical practice guidelines recommend that enteral nutrition (EN) be commenced through a nasogastric tube, usually within the first 24-48 hrs after intensive care unit (ICU) admission (4) (5) (6) (7) .
Observational studies have consistently shown that critically ill adults are delivered between 49%-70% of estimated energy requirements (8) (9) (10) (11) (12) . The optimal energy delivery amount is controversial, but attempts to increase delivery are often hampered by gastric intolerance of EN. Gastric intolerance has been associated with narcotic analgesic and vasopressor infusions (13) , and is an important risk factor for reduced energy delivery and hospital-acquired pneumonia (14) .
Delivery of nutrition into the small bowel using a nasojejunal tube may be preferable to nasogastric delivery as the small bowel has greater absorptive capacity (15) and is less subject to impaired motility (16) . Nutrition is delivered further away from the pharynx and respiratory tree, potentially reducing the risk of pneumonia from gastroesophageal regurgitation (17) . Nasojejunal nutrition decreases gastric residual volumes (GRV) (18) , which would be expected to lead to fewer interruptions to EN.
Studies comparing nasojejunal and nasogastric nutrition in adult ICU patients have reported inconsistent results regarding both nutritional energy delivery and occurrence rate of pneumonia (18) (19) (20) (21) (22) (23) (24) (25) . Previous trials mostly included low-risk patients (where nasogastric nutrition was unlikely to be problematic), and we considered that early nasojejunal nutrition might have its greatest effect in ICU patients experiencing poor gastric motility (as manifest by elevated GRVs) such as those requiring narcotic infusions and mechanical ventilation. Our primary objective was to determine whether early nasojejunal nutrition, when compared to nasogastric nutrition, would increase energy delivery. Secondary objectives were to compare the effects on the occurrence rate of ventilator-associated pneumonia (VAP) and other clinical outcomes.
MATERIALS AND METHODS
We conducted a parallel-group, randomized, controlled trial in 17 closed, multidisciplinary, medical-surgical ICUs in Australia (ten university-affiliated metropolitan hospitals and seven community/rural hospitals). All sites received institutional human research ethics committee approval, and prior written informed consent was obtained from the patient's surrogate decision maker.
Inclusion criteria were: age ≥18 yrs; ICU stay <48 hrs; receiving mechanical ventilation with ≥48 hrs anticipated duration; receiving narcotic infusion (morphine ≥2 mg/hr, fentanyl ≥20 mcg/hr, or meperidine ≥20 mg/hr); elevated GRV (single measurement >150 mL or 12 hr cumulative volume >500 mL). Patients could already have commenced EN. After an initial 6-month period with slower-than-anticipated enrolment rates, the relevant inclusion criteria were modified to age ≥16 yrs, ICU stay <72 hrs, and receiving narcotic infusion at any dose. Exclusion criteria were: previous anatomyaltering upper gastrointestinal surgery, gastric malignancy, esophageal varices, current peptic ulceration, mechanical bowel obstruction, presence of gastrostomy or jejunostomy, nutrition therapy prior to ICU admission, severe coagulopathy, pregnancy, suspected brain death, death expected within 24 hrs, and suspected hypoxic-ischemic encephalopathy.
At randomization, patients were stratified by site and by the presence of a vasopressor infusion (defined as any current dose of epinephrine or norepinephrine). They were randomly assigned to early nasojejunal nutrition or nasogastric nutrition using a computer-generated randomization schedule with variable block size. Treatment assignments were concealed before randomization using a centralized voice-recognition phone system. There was no blinding after randomization, however, all patients had energy requirements objectively estimated using the Schofield equation (26) prior to randomization to minimize bias in primary outcome assessment. Stress factors relevant to the clinical situation were applied to the estimated basal requirement (using measured or estimated weight) to determine the total daily energy requirement, which was then converted to an hourly target EN volume, and which remained unchanged throughout the study period. The type of EN formulation delivered, including its energy concentration, was at the discretion of the clinical team.
Patients assigned to early nasojejunal nutrition had a spontaneously migrating frictional nasojejunal tube (Tiger tube, Cook Critical Care, Bloomington, IN) inserted using a standardized method. Essential aspects of this method were initial gastric positioning by tube insertion to 40-50 cm from the nostril, intravenous administration of 250-mg erythromycin, and hourly 10-cm tube advancement to a maximum of 100 cm from the nostril to allow passage into the small bowel (preferably jejunum). As soon as practicable, tube position was assessed using plain radiograph without contrast. If the tube was not positioned in the jejunum, time was allowed for further spontaneous passage using further doses of erythromycin as needed, sometimes with tube repositioning prior to repeat radiograph. If the nasojejunal tube had not passed beyond the gastric pylorus after either 48 hrs or after use of 2 individual tubes, an alternative nasojejunal tube insertion technique was recommended. Patients with successfully positioned nasojejunal tubes also had a nasogastric tube placed to assess GRVs.
All patients assigned to nasogastric nutrition had a nasogastric tube already in situ. EN was then commenced as part of the study for both groups when the enteral tube was successfully positioned beyond the gastro-esophageal junction. The initial commencement rate and advancement rate toward the hourly target were determined by each hospital's standard practice, but the aim was to meet estimated energy requirements as soon as possible by following a locally developed evidence-based algorithm (6) . Patients with clinical manifestations of EN intolerance received metoclopramide (10 mg intravenously every 6-hours), followed by erythromycin (250 mg intravenously every 12-hours) if required. If EN intolerance persisted despite >48 hrs of promotility drug treatment, nasogastric group patients could have a nasojejunal tube inserted using the hospital's standard insertion method.
The study nutrition period was continued until 28 days after enrolment, death, ICU discharge, or until the patient began eating, whichever came first; subsequent nutritional management was at the discretion of the clinical team. The patients were followed until hospital discharge.
Other recommended treatments for all patients were head of bed elevation to 45 degrees and ranitidine for stress ulcer prophylaxis (except for patients receiving a proton-pump inhibitor prior to ICU admission). Clinicians followed an algorithm for the diagnosis of VAP (Supplemental Digital Appendix A, Supplemental Digital Content 1, http://links. lww.com/CCM/A454), modified from a previous trial (27) , however, clinical VAP management was at their discretion.
The primary outcome measure was energy delivery from EN, calculated as a proportion of estimated energy requirements from enrolment to the end of ICU stay (up to 28 days).
Secondary outcome measures were VAP incidence, mechanical ventilation and hospitalization durations, and in-hospital mortality rate.
Trained research coordinators collected data, which included patient demographics, enteral tube-related characteristics, and all nutrition delivered after enrolment. Patients were observed for clinically-suspected VAP, vomiting, abdominal distension (defined as either symptomatic in an awake cooperative patient or increasing abdominal girth on serial measurements), witnessed pulmonary aspiration, gastrointestinal hemorrhage (defined as major or minor based on definitions from a previous trial) (27; Supplemental Digital Appendix B, Supplemental Digital Content 1, http://links.lww.com/CCM/A454), and other adverse events. If patients developed clinically-suspected VAP, additional data were collected including body temperature, white blood cell count, sputum amount and appearance, Pao 2 /Fio 2 ratios, microbiological culture results, histopathology results, antibiotic usage, and chest radiograph images over the time period from 3 days before to 3 days after its development. The collected information was provided to a blinded adjudication panel of two intensivists and one respiratory physician for each patient. To maintain blinding, the radiograph images had the enteral tube shadows in the mediastinum and upper abdomen obscured. Panel members individually adjudicated the diagnosis of VAP using objective criteria (Supplemental Digital Appendix A, Supplemental Digital Content 1, http://links.lww. com/CCM/A454). Patients were formally categorized as meeting the VAP outcome if at least two of the three adjudicators determined the presence of VAP and this occurred after the patient had been mechanically ventilated for >72 hrs. A Data Monitoring Committee regularly viewed data on safety aspects with blinding maintained and did not recommend study cessation.
The 180-patient sample size provided 80% power with two-sided significance of 0.05 to detect a 12% difference in mean energy delivery, as a proportion of estimated energy requirements, from a baseline estimate that the nasogastric group would receive 60% of their targeted energy delivery, using an estimated standard deviation of 28% from our previous study (18) . Data were analyzed according to the intention-to-treat principle with no imputation of missing values. The primary outcome (proportion of estimated energy requirements delivered from EN) was calculated by dividing the total energy received from EN by the total predicted energy requirement for the study nutrition period. Group comparisons were made using Student t tests for normally distributed data, Wilcoxon rank sum tests for nonparametric data and chi-square tests for proportions. As the proportion of estimated energy requirements delivered from EN was found to be well approximated by a normal distribution, a secondary analysis using repeat measures analysis of variance was also performed by fitting group and time effects along with an interaction between group and time to determine whether the two groups behaved differently over time. Prespecified subgroup analyses were performed in patients with enrolment Acute Physiology and Chronic Health Evaluation II (28) scores ≥20 and <20 and patients receiving a vasopressor infusion at enrolment or not. Analyses were performed using SAS version 9.1 (SAS Institute, Cary, NC); a two-sided p value of .05 was considered statistically significant.
RESULTS
We screened 3,623 patients, of whom 1,453 met inclusion criteria ( Fig. 1 ). From these, 773 met exclusion criteria, 59 had consent declined, 335 could not be enrolled due to participation in another trial or unavailability of staff or surrogate decision makers, and 105 had other reasons not to be enrolled. This meant that 181 patients were enrolled with 92 assigned to early nasojejunal nutrition and 89 to nasogastric nutrition. Consent was withdrawn for one early nasojejunal patient, meaning 91 early nasojejunal and 89 nasogastric patients completed the study and were analyzed.
The baseline characteristics of the groups were similar (Table 1) . Patients were enrolled after a mean sd of 42 (15) and 43 (17) hrs in ICU for the early nasojejunal and nasogastric group, respectively. At enrollment, the majority of patients in each group had already begun to receive EN via a nasogastric tube and were receiving vasopressors. The mean predicted energy requirements were similar and were just above 2200 kcal/day for both groups.
All 91 patients assigned to the early nasojejunal nutrition group had nasojejunal tube placement attempted. Radiographic confirmation of small bowel placement occurred in 79 (87%) patients, of which 60 (66%) had passed into the jejunum and 19 (21%) into the duodenum. In those with successful small bowel placement, this was confirmed after a median of 15 (interquartile range 7-32) hrs and a median of 2 (interquartile range 1-3, maximum 8) radiographs. The nasojejunal tube was successfully placed within 48 hrs in 76 (84%) patients. The nasojejunal tube did not advance past the stomach in 12 (13%) patients.
All 89 patients assigned to the nasogastric group received EN through a nasogastric tube. Both groups received EN for a median of 8 (interquartile range 5-14) days. Metoclopramide was administered to 82 (90%) patients in the early nasojejunal and 81 (91%) in the nasogastric groups, respectively (p = .84). Erythromycin was more commonly used in the early nasojejunal group than the nasogastric group (79 [87%] vs. 55 [62%] patients; p = .001). Nasojejunal tubes were placed in The proportion of estimated energy requirements delivered from EN during the study period was 72% (sd 21%) for the early nasojejunal and 71% (sd 19%) for the nasogastric group (mean difference 1%, 95% confidence interval −3% to 5%, p = .66, Table 2 ). The early nasojejunal and the nasogastric groups received a mean daily energy amount of 1497 kcal and 1444 kcal, respectively (mean difference 53 kcal, 95% confidence interval −56 to 162, p = .49). The proportion of target energy delivered by EN over the first 10 days of the study period was also 72% and 71%, respectively (mean difference 1%, 95% confidence interval −3% to 5%, p = .76). On the basis of the secondary analysis, the daily proportions of target energy delivered for the first 10 days were similar for both groups (Fig. 2) .
The blinded adjudication panel diagnosed VAP in 18 (20%) patients in the early nasojejunal group compared with 19 (21%) in the nasogastric group (p = .94, Table 3 ). Rates of vomiting, witnessed aspiration, abdominal distension, diarrhea, and accidental withdrawal of the enteral tube were similar. Major hemorrhage rates were also similar (2 (2%) vs. 2 (2%), respectively, p = .98). However, minor hemorrhage was more common in the early nasojejunal group (12 [13%] vs. 3 [3%], p = .02). There were no statistically significant differences in duration of ICU stay (p = .85), hospitalization (p = .57), and in-hospital mortality (p = .88) ( Table 3) .
Prespecified subgroup analyses found no significant outcome differences for patients with Acute Physiology and Chronic Health Evaluation II scores ≥20 and <20 and patients receiving or not receiving vasopressor infusions at enrolment (Table 4) . A post hoc analysis that compared early nasojejunal group patients (79) where the tube had reached the small bowel with nasogastric group patients (89) found no significant outcome differences (Supplemental Digital Appendix D, Supplemental Digital Content 1, http://links.lww.com/CCM/A454).
DISCUSSION
Key Findings. We performed a randomized controlled trial of early nasojejunal compared with nasogastric nutrition in ICU patients with high-risk features for impaired tolerance of nasogastric nutrition. We found that early nasojejunal nutrition did not increase the amount of energy delivered. There were also no differences in the rates of VAP, vomiting, witnessed aspiration, abdominal distension, duration of mechanical ventilation, and hospitalization, and mortality. Nasojejunal tubes were successfully positioned in the small bowel, particularly the jejunum, in the majority of patients. Nasojejunal-tube placement was associated with an increased rate of minor gastrointestinal hemorrhage.
Comparison With Previous Studies. Several randomized controlled trials of nasojejunal vs. nasogastric nutrition in ICU patients have found that nasojejunal nutrition increased energy delivery (20, 21, 24, 25) . In this larger study we did not find this benefit. We studied a sub-population of ICU patients at risk for EN intolerance by identifying patients with risk factors for, and markers of, poor gastric motility. Vomiting was common in both groups, reflecting this reduced gastric motility; however, delivering nutrition below the gastric pylorus did not reduce vomiting. A high proportion of the nasogastric nutrition group received metoclopramide or erythromycin, which may have explained why they received >70% of energy requirements and the lack of benefit of early nasojejunal nutrition; however greater erythromycin use in the early nasojejunal group (mostly for tube placement) did not lead to improved energy delivery.
In contrast to a recent study (24) , VAP rates were not significantly reduced by delivering nutrition into the small (15) ICU, intensive care unit. bowel rather than the stomach. A metaanalysis suggested nasojejunal nutrition might reduce pneumonia rates in ICU patients (29) ; however based on our results the effect is likely to be small and a study of several thousand patients would be required to confirm or refute such findings.
Strengths and Limitations.
A strength of our study was its multicenter nature, increasing its external validity and applicability to clinical practice. To our knowledge, it is the largest study comparing small bowel and gastric delivery conducted in ICU patients. An important limitation was the lack of blinding. But whereas treating clinicians were not blinded to treatment assignment, study validity was strengthened by use of a standardized evidence-based nutrition algorithm, estimation of energy requirements using a standardized prerandomization assessment, and blinded outcome adjudication for VAP diagnosis. A limitation is that we enrolled patients who had commenced nasogastric nutrition prior to enrolment (>90% of patients) and who had on average been in ICU for approximately 42 hrs at randomization. Such exposure to nasogastric nutrition may have reduced the efficacy of nasojejunal nutrition in reducing VAP incidence. There are significant logistic difficulties in screening and enrolling patients into a study before they commence EN as it is commonly begun early (3). We used a conservative definition of elevated GRV (>150 mL). Elevated GRV is a practical and easily identifiable criterion that translates to the practising clinician but may not have identified a population of patients with significant impairment to gastric emptying. We may have studied patients who were either only mildly EN intolerant or who were beyond the time period of maximal intolerance, explaining why the nasogastric nutrition group was delivered >70% of estimated energy requirements, therefore reducing the chance of nasojejual nutrition being effective in improving delivery of energy requirements. We also allowed some nasogastric patients (9%) to cross over to nasojejunal nutrition. We cannot exclude the possibility that earlier nasojejunal tube placement might be beneficial, in general and especially in centers that cannot achieve high EN delivery using nasogastric nutrition, or when promotility use is lower. Our findings with regard to VAP are strengthened by the use of a blinded outcome adjudication panel to minimize bias, but are weakened because the group assigned to early nasojejunal nutrition received nasogastric nutrition either throughout the study in some patients (the nasojejunal tube did not pass beyond the stomach in 13%) or initially in many others (passage of the nasojejunal tube into the small bowel was confirmed a median of 15 hrs after randomization). Patients mostly received norepinephrine as the vasopressor. After stratified randomization whereas receiving a vasopressor, norepinephrine was administered to 73 and 67 patients for a median (IQR) of 4 (3-7) and 4 (2-6) days at a median dose of 0.152 and 0.117 mcg/kg in the early jejunal and gastric groups, respectively (1 early jejunal patient did not receive a vasopressor after randomisation). After stratified randomization wereas not receiving a vasopressor, norepinephrine was administered to 6 and 12 patients for a median (IQR) of 2.5 (2-3) and 1 (1-1) days at a median dose of 0.124 and 0.117 mcg/ kg in the early jejunal and gastric groups, respectively. Clinical Implications and Future Studies. Early nasojejunal nutrition is not routine in international critical care practice (12) . Most evidence-based guidelines (5-7) recommend the initial use of nasogastric nutrition, although one guideline recommends nasojejunal tubes be placed in mechanically ventilated patients where this is feasible, or at least when the risk of pneumonia is high (4) . Guidelines consistently recommend that nasojejunal nutrition be used when elevated GRVs occur (4-7). Our study refutes this recommendation for this practice in the early period of ICU management (the first 3 days) but does not assist clinicians in decision-making when intolerance of nasogastric nutrition persists beyond several days or in patients who are not receiving narcotic infusions.
CONCLUSIONS
We found that in ICU patients with mildly elevated GRVs and already receiving nasogastric nutrition, early nasojejunal nutrition (in the first few days) did not increase energy delivery or reduce the occurrence rate of pneumonia; however, it increased the risk of minor gastrointestinal hemorrhage. Routine placement of a nasojejunal tube in such patients is not recommended. Patients who received nasogastric nutrition received over 70% of their estimated energy requirements. If improvement on this amount is required, interventions other than nasojejunal nutrition should be considered.
